No Data
No Data
10-Q: Quarterly report
XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities
XOMA Adds Economic Interests in Three First-in-Category Assets to Its Royalty and Milestone Portfolio Including XACIATO (Clindamycin Phosphate) Vaginal Gel 2%
Organon, a global women's healthcare company, initiated XACIATO commercial activities in the fourth quarter of 2023 XOMA further expands its late-stage portfolio with synthetic royalty and milestone interests in
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One's OJEMDATM (Tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (PLGG)
XOMA is entitled to a mid-single digit royalty on global OJEMDA sales First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or
XOMA Corporation Announces Closing of Tender Offer
Kinnate Stockholders to Receive $2.5879 Per Share in Cash Plus Contingent Value RightEMERYVILLE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) ("XOMA" or the "Company"),
XOMA CORP DEPOSITARY SH REPR 1/1000TH B CUM PERP P To Go Ex-Dividend On April 2nd, 2024 With 0.52344 USD Dividend Per Share
March 22nd - $XOMA CORP DEPOSITARY SH REPR 1/1000TH B CUM PERP P(XOMAO.US)$ is trading ex-dividend on April 2nd, 2024. Shareholders of record on April 3rd, 2024 will receive 0.52344 USD dividend p
No Data